In an in vitro model of Parkinson’s disease (PD), Tyr treatment protected catecholaminergic cells from 1-methyl-4-phenylpyridinium (MPP+)-induced cell death, possibly through activation of the PI3K/Akt signaling pathway [31]. This evidence concerns the gene AKT1 and Parkinson disease.